A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers

Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. The purpose of this study was to develop a translational, caffeine-induced model of insomni...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacologia Vol. 191; no. 4; pp. 943 - 950
Main Authors Paterson, Louise M., Wilson, Sue J., Nutt, David J., Hutson, Peter H., Ivarsson, Magnus
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.05.2007
Springer Nature B.V
Subjects
Rat
Online AccessGet full text

Cover

Loading…
Abstract Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.
AbstractList Rationale: Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. Objectives: The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. Materials and methods: In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Results: Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. Conclusions: This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.
Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic.RATIONALEInsomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic.The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively.OBJECTIVESThe purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively.In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire.MATERIALS AND METHODSIn rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire.Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers.RESULTSCaffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers.This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.CONCLUSIONSThis model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.
Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans.
Rationale Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate animal models to assess likely outcome in the clinic. Objectives The purpose of this study was to develop a translational, caffeine-induced model of insomnia in rats and healthy volunteers. We used sleep onset latency (SOL) as a comparable sleep measure between the two species. The model was validated by two effective sleep-promoting agents with different pharmacology, zolpidem and trazodone, which have GABA-ergic and serotonergic mechanisms, respectively. Materials and methods In rats, radiotelemetry transmitters with electroencephalogram and electromyogram electrodes were implanted for sleep recording. Animals were administered with caffeine alone (10 mg/kg) or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg), or vehicle, in crossover experiments. Home polysomnography was performed in 12 healthy male volunteers in a randomised, placebo-controlled, 4-week crossover study. Subjects received placebo, caffeine (150 mg) or caffeine in combination with zolpidem (10 mg) or trazodone (100 mg). Subjective sleep effects in volunteers were assessed using the Leeds Sleep Evaluation Questionnaire. Results Caffeine caused a significant prolongation in objective SOL in rats and humans. This effect was sensitive to zolpidem and trazodone, both of which attenuated the caffeine-induced increase in SOL. Furthermore, both hypnotics restored the disruption in subjective measures of sleep onset caused by caffeine in volunteers. Conclusions This model therefore provides a promising paradigm in which we can study novel treatments for sleep disorders and an opportunity for direct comparison of results between rodents and humans. [PUBLICATION ABSTRACT]
Author Hutson, Peter H.
Wilson, Sue J.
Nutt, David J.
Ivarsson, Magnus
Paterson, Louise M.
Author_xml – sequence: 1
  givenname: Louise M.
  surname: Paterson
  fullname: Paterson, Louise M.
– sequence: 2
  givenname: Sue J.
  surname: Wilson
  fullname: Wilson, Sue J.
– sequence: 3
  givenname: David J.
  surname: Nutt
  fullname: Nutt, David J.
– sequence: 4
  givenname: Peter H.
  surname: Hutson
  fullname: Hutson, Peter H.
– sequence: 5
  givenname: Magnus
  surname: Ivarsson
  fullname: Ivarsson, Magnus
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18677076$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17225163$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1rFTEUhoNU7G31B7iRIOjK0ZNkJsksS_ELCm4U3IUz-aApmaROZgr99-Z6rxS60GxOFs85nPM-Z-Qkl-wJecngPQNQHyoAZ6IDkB1IxTt4QnasF7zjoPgJ2QEI0Qk26FNyVusNtNfr_hk5ZYrzgUmxIz8v6LpgrgnXWDKmd9RiCD5m38XsNusdnYvziZZAS65-pTHXMueI7UMXXCvF7Oi1x7Re39O7kra8er_U5-RpwFT9i2M9Jz8-ffx--aW7-vb56-XFVWf7QaxdcEKKSbKg0bpeSfCIY7st8DAqpwPiNLhJg5jGaXJOcRuGAAiDCJox68Q5eXuYe7uUX5uvq5ljtT4lzL5s1SjgUiot_guyUfagBTTw9SPwpmxLy6YazvQ4SA77aa-O0DbN3pnbJc643Ju_yTbgzRHAajGFFrKN9YHTUilQsnHswNml1Lr48ICA2Vs2B8umWTZ7y2a_oXrUY-P6R2BzGdM_On8DdnGqxg
CODEN PSYPAG
CitedBy_id crossref_primary_10_3390_nu15041042
crossref_primary_10_1177_0748730418789236
crossref_primary_10_1523_JNEUROSCI_1809_08_2008
crossref_primary_10_1089_jcr_2011_0030
crossref_primary_10_1177_2165079915579561
crossref_primary_10_1248_bpb_b19_00454
crossref_primary_10_1016_j_jsmc_2019_01_007
crossref_primary_10_1016_j_yrtph_2015_12_002
crossref_primary_10_1155_2018_7196142
crossref_primary_10_1177_14727978241299575
crossref_primary_10_1039_C9RA01549C
crossref_primary_10_3390_nu11030556
crossref_primary_10_1016_j_ejphar_2014_09_012
crossref_primary_10_1177_0269881109104852
crossref_primary_10_1093_sleep_zsad112
crossref_primary_10_1186_1753_4631_5_4
crossref_primary_10_4062_biomolther_2016_156
crossref_primary_10_1016_j_pnpbp_2015_05_006
crossref_primary_10_1038_s41401_024_01269_w
crossref_primary_10_1177_0269881111400643
crossref_primary_10_3390_nu14112249
crossref_primary_10_1177_0269881110379307
crossref_primary_10_1016_j_neubiorev_2009_03_002
crossref_primary_10_1111_j_1601_183X_2011_00719_x
crossref_primary_10_1111_j_1747_0080_2012_01601_x
crossref_primary_10_1016_j_fitote_2014_04_017
crossref_primary_10_1586_ecp_10_138
crossref_primary_10_1111_bph_12782
crossref_primary_10_12968_hmed_2009_70_6_327
crossref_primary_10_4162_nrp_2018_12_3_208
crossref_primary_10_1177_09645284211011489
crossref_primary_10_1016_j_fct_2017_04_002
crossref_primary_10_1177_0960327118769717
crossref_primary_10_1016_j_pbb_2012_01_011
crossref_primary_10_1177_0269881109104846
crossref_primary_10_1016_j_jfda_2016_05_005
crossref_primary_10_3390_bs8080065
Cites_doi 10.1016/j.ejphar.2004.09.054
10.1046/j.1460-9568.1998.00069.x
10.1097/00004714-199006000-00005
10.1002/j.1875-9114.1982.tb03193.x
10.1016/j.ejphar.2005.08.050
10.1016/1043-6618(94)80002-2
10.1046/j.1440-1819.1998.00403.x
10.1016/S0165-0270(02)00148-6
10.1007/BF00432545
10.1016/S0014-2999(02)02915-1
10.1007/BF02244546
10.1016/S0091-3057(97)00595-9
10.1001/jama.1997.03550240060035
10.1002/hup.470030104
10.1016/S0006-8993(02)02698-7
10.1016/S0149-2918(00)83043-X
10.1002/hup.445
10.1017/S0033291700014379
10.1177/026988110001400420
10.1016/S0021-9673(00)97841-5
10.1016/0014-2999(96)00021-0
10.1002/(SICI)1099-1077(199605)11:3<185::AID-HUP786>3.0.CO;2-M
10.4088/JCP.v66n0409
10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X
10.1111/j.1365-2125.1983.tb04977.x
10.1016/S0924-9338(99)80736-6
10.1016/j.brainres.2005.08.015
10.1097/00004714-199504000-00009
10.1093/sleep/27.3.536
10.1007/s002130000383
10.1093/sleep/22.1.33
10.1016/j.clpt.2003.11.375
10.1002/cpt1976206682
ContentType Journal Article
Copyright 2007 INIST-CNRS
Springer-Verlag 2007
Copyright_xml – notice: 2007 INIST-CNRS
– notice: Springer-Verlag 2007
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7U7
C1K
7X8
DOI 10.1007/s00213-006-0672-0
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Engineering Research Database
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Psychology Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Toxicology Abstracts
MEDLINE - Academic
MEDLINE
ProQuest One Psychology
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-2072
EndPage 950
ExternalDocumentID 1231721161
17225163
18677076
10_1007_s00213_006_0672_0
Genre Validation Studies
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID .55
3SX
40D
40E
95.
95~
AAYXX
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CITATION
KOW
N2Q
R9-
RHV
SBY
SOJ
X7M
~EX
IQODW
-4W
-BR
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GNUQQ
K9.
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7U7
C1K
7X8
ID FETCH-LOGICAL-c453t-fd363b61f8acd4760eaa9007f2f97d8faab5db803b9bbdd72cf5f0a053f811cd3
IEDL.DBID 7X7
ISSN 0033-3158
IngestDate Fri Jul 11 06:03:33 EDT 2025
Thu Jul 10 18:14:44 EDT 2025
Sun Aug 17 12:10:56 EDT 2025
Sat Sep 28 07:57:22 EDT 2024
Wed Apr 02 07:25:59 EDT 2025
Thu Apr 24 23:04:59 EDT 2025
Tue Jul 01 04:16:30 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Agonist
Telemetry·Caffeine·Zolpidem· Trazodone Sleep
Rat
Psychotropic
Benzodiazepine receptor
Trazodone
Bicyclic compound
Antidepressant agent
Xanthine derivatives
Neurological disorder
Caffeine
Human
Nervous system diseases
Healthy subject
CNS stimulant
Gabaergic agonist
Rodentia
Sleep disorder
Hypnotic
Polysomnography
Vertebrata
Mammalia
Sleep
Tranquillizer
Insomnia
Animal
Zolpidem
Models
Piperazine derivatives
Gabaergic receptor A
Healthy volunteer- Rat
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c453t-fd363b61f8acd4760eaa9007f2f97d8faab5db803b9bbdd72cf5f0a053f811cd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
PMID 17225163
PQID 218956203
PQPubID 47309
PageCount 8
ParticipantIDs proquest_miscellaneous_70266783
proquest_miscellaneous_19640830
proquest_journals_218956203
pubmed_primary_17225163
pascalfrancis_primary_18677076
crossref_primary_10_1007_s00213_006_0672_0
crossref_citationtrail_10_1007_s00213_006_0672_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-05-01
PublicationDateYYYYMMDD 2007-05-01
PublicationDate_xml – month: 05
  year: 2007
  text: 2007-05-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacologia
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 2007
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
References R Cluydts (672_CR5) 1995; 15
AC Parrott (672_CR28) 1978; 8
CA Haller (672_CR12) 2004; 75
D Drover (672_CR7) 2000; 22
V Vogel (672_CR34) 2002; 118
A Rechtschaffen (672_CR30) 1968
K Shinomiya (672_CR33) 2004; 504
MH Bonnet (672_CR2) 1992; 15
JK Walsh (672_CR35) 1990; 10
I Montgomery (672_CR22) 1983; 16
JK Walsh (672_CR36) 1998; 13
Y Wang (672_CR37) 1998; 60
SJ Wilson (672_CR38) 2000; 14
M Ivarsson (672_CR16) 2005; 522
C Gottesmann (672_CR10) 1998; 10
B Schwierin (672_CR31) 1996; 300
WB Mendelson (672_CR21) 2005; 66
I Hindmarch (672_CR13) 1988; 3
I Hindmarch (672_CR14) 2000; 149
A Georgotas (672_CR9) 1982; 2
D Garrigou-Gadenne (672_CR8) 1989; 248
PM Haffmans (672_CR11) 1999; 14
MJ Owens (672_CR27) 1997; 283
S Caccia (672_CR4) 1981; 210
A Rabat (672_CR29) 2005; 1059
S Kantor (672_CR17) 2002; 943
H Depoortere (672_CR6) 1986; 237
DP Brunner (672_CR3) 1991; 104
M Lancel (672_CR19) 1999; 22
C Iber (672_CR15) 2004; 27
CA Alford (672_CR1) 1996; 11
J Montplaisir (672_CR23) 2003; 18
K Shinomiya (672_CR32) 2003; 460
Z Lelkes (672_CR20) 1994; 30
PD Nowell (672_CR25) 1997; 278
672_CR24
H Yamadera (672_CR39) 1998; 52
I Karacan (672_CR18) 1976; 20
T Okuma (672_CR26) 1982; 76
9766695 - Psychiatry Clin Neurosci. 1998 Aug;52(4):439-43
9749703 - Eur J Neurosci. 1998 Feb;10(2):409-14
2871178 - J Pharmacol Exp Ther. 1986 May;237(2):649-58
12559374 - Eur J Pharmacol. 2003 Jan 24;460(2-3):139-44
11192136 - Clin Ther. 2000 Dec;22(12 ):1443-61
10572343 - Eur Psychiatry. 1999 Jun;14(3):167-71
6763207 - Pharmacotherapy. 1982 Sep-Oct;2(5):255-65
7816739 - Pharmacol Res. 1994 Aug-Sep;30(2):105-15
6615688 - Br J Clin Pharmacol. 1983 Aug;16(2):139-44
7782486 - J Clin Psychopharmacol. 1995 Apr;15(2):132-7
9417012 - JAMA. 1997 Dec 24-31;278(24):2170-7
9400006 - J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22
11198056 - J Psychopharmacol. 2000;14(4):378-86
8739204 - Eur J Pharmacol. 1996 Apr 11;300(3):163-71
1881993 - Psychopharmacology (Berl). 1991;104(1):1-5
12532313 - Hum Psychopharmacol. 2003 Jan;18(1):29-38
2198296 - J Clin Psychopharmacol. 1990 Jun;10(3):184-9
9610952 - Pharmacol Biochem Behav. 1998 May;60(1):271-8
7263792 - J Chromatogr. 1981 Jun 5;210(2):311-8
15060505 - Clin Pharmacol Ther. 2004 Apr;75(4):259-73
15164911 - Sleep. 2004 May 1;27(3):536-40
15541420 - Eur J Pharmacol. 2004 Nov 19;504(3):185-9
2703975 - J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8
9989364 - Sleep. 1999 Feb 1;22(1):33-42
16168393 - Brain Res. 2005 Oct 12;1059(1):72-82
12088844 - Brain Res. 2002 Jul 5;943(1):105-11
26096 - Psychol Med. 1978 May;8(2):325-9
6124991 - Psychopharmacology (Berl). 1982;76(3):201-8
10823400 - Psychopharmacology (Berl). 2000 Apr;149(3):203-16
16223479 - Eur J Pharmacol. 2005 Oct 17;522(1-3):63-71
1475567 - Sleep. 1992 Dec;15(6):526-36
12191761 - J Neurosci Methods. 2002 Jul 30;118(1):89-96
15816789 - J Clin Psychiatry. 2005 Apr;66(4):469-76
186223 - Clin Pharmacol Ther. 1976 Dec;20(6):682-9
References_xml – volume: 504
  start-page: 185
  year: 2004
  ident: 672_CR33
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2004.09.054
– volume: 10
  start-page: 409
  year: 1998
  ident: 672_CR10
  publication-title: Eur J Neurosci
  doi: 10.1046/j.1460-9568.1998.00069.x
– volume: 10
  start-page: 184
  year: 1990
  ident: 672_CR35
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199006000-00005
– volume: 2
  start-page: 255
  year: 1982
  ident: 672_CR9
  publication-title: Pharmacotherapy
  doi: 10.1002/j.1875-9114.1982.tb03193.x
– volume: 522
  start-page: 63
  issue: 1–3
  year: 2005
  ident: 672_CR16
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2005.08.050
– volume: 30
  start-page: 105
  year: 1994
  ident: 672_CR20
  publication-title: Pharmacol Res
  doi: 10.1016/1043-6618(94)80002-2
– volume: 237
  start-page: 649
  year: 1986
  ident: 672_CR6
  publication-title: J Pharmacol Exp Ther
– volume: 52
  start-page: 439
  year: 1998
  ident: 672_CR39
  publication-title: Psychiatry Clin Neurosci
  doi: 10.1046/j.1440-1819.1998.00403.x
– volume: 118
  start-page: 89
  issue: 1
  year: 2002
  ident: 672_CR34
  publication-title: J Neurosci Methods
  doi: 10.1016/S0165-0270(02)00148-6
– volume: 76
  start-page: 201
  year: 1982
  ident: 672_CR26
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF00432545
– volume: 460
  start-page: 139
  year: 2003
  ident: 672_CR32
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(02)02915-1
– volume: 104
  start-page: 1
  issue: 1
  year: 1991
  ident: 672_CR3
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/BF02244546
– volume: 60
  start-page: 271
  year: 1998
  ident: 672_CR37
  publication-title: Pharmacol Biochem Behav
  doi: 10.1016/S0091-3057(97)00595-9
– volume: 278
  start-page: 2170
  year: 1997
  ident: 672_CR25
  publication-title: JAMA
  doi: 10.1001/jama.1997.03550240060035
– volume: 3
  start-page: 13
  year: 1988
  ident: 672_CR13
  publication-title: Hum Psychopharmacol Clin Exp
  doi: 10.1002/hup.470030104
– volume: 943
  start-page: 105
  year: 2002
  ident: 672_CR17
  publication-title: Brain Res
  doi: 10.1016/S0006-8993(02)02698-7
– volume: 22
  start-page: 1443
  year: 2000
  ident: 672_CR7
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(00)83043-X
– volume: 18
  start-page: 29
  year: 2003
  ident: 672_CR23
  publication-title: Hum Psychopharmacol
  doi: 10.1002/hup.445
– volume: 8
  start-page: 325
  year: 1978
  ident: 672_CR28
  publication-title: Psychol Med
  doi: 10.1017/S0033291700014379
– volume: 14
  start-page: 378
  year: 2000
  ident: 672_CR38
  publication-title: J Psychopharmacol
  doi: 10.1177/026988110001400420
– volume: 210
  start-page: 311
  year: 1981
  ident: 672_CR4
  publication-title: J Chromatogr
  doi: 10.1016/S0021-9673(00)97841-5
– volume: 283
  start-page: 1305
  year: 1997
  ident: 672_CR27
  publication-title: J Pharmacol Exp Ther
– volume: 300
  start-page: 163
  year: 1996
  ident: 672_CR31
  publication-title: Eur J Pharmacol
  doi: 10.1016/0014-2999(96)00021-0
– volume: 11
  start-page: 185
  year: 1996
  ident: 672_CR1
  publication-title: Hum Psychopharmacol Clin Exp
  doi: 10.1002/(SICI)1099-1077(199605)11:3<185::AID-HUP786>3.0.CO;2-M
– volume: 66
  start-page: 469
  year: 2005
  ident: 672_CR21
  publication-title: J Clin Psychiatry
  doi: 10.4088/JCP.v66n0409
– volume: 13
  start-page: 191
  year: 1998
  ident: 672_CR36
  publication-title: Hum Psychopharmacol
  doi: 10.1002/(SICI)1099-1077(199804)13:3<191::AID-HUP972>3.0.CO;2-X
– ident: 672_CR24
– volume-title: A manual of standardised terminology: techniques and scoring system for sleep stages of human subjects
  year: 1968
  ident: 672_CR30
– volume: 248
  start-page: 1283
  year: 1989
  ident: 672_CR8
  publication-title: J Pharmacol Exp Ther
– volume: 16
  start-page: 139
  year: 1983
  ident: 672_CR22
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/j.1365-2125.1983.tb04977.x
– volume: 14
  start-page: 167
  year: 1999
  ident: 672_CR11
  publication-title: Eur Psychiatry
  doi: 10.1016/S0924-9338(99)80736-6
– volume: 1059
  start-page: 72
  year: 2005
  ident: 672_CR29
  publication-title: Brain Res
  doi: 10.1016/j.brainres.2005.08.015
– volume: 15
  start-page: 526
  year: 1992
  ident: 672_CR2
  publication-title: Sleep
– volume: 15
  start-page: 132
  year: 1995
  ident: 672_CR5
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199504000-00009
– volume: 27
  start-page: 536
  year: 2004
  ident: 672_CR15
  publication-title: Sleep
  doi: 10.1093/sleep/27.3.536
– volume: 149
  start-page: 203
  year: 2000
  ident: 672_CR14
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s002130000383
– volume: 22
  start-page: 33
  year: 1999
  ident: 672_CR19
  publication-title: Sleep
  doi: 10.1093/sleep/22.1.33
– volume: 75
  start-page: 259
  year: 2004
  ident: 672_CR12
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.11.375
– volume: 20
  start-page: 682
  issue: 6
  year: 1976
  ident: 672_CR18
  publication-title: Clin Pharmacol Ther
  doi: 10.1002/cpt1976206682
– reference: 9610952 - Pharmacol Biochem Behav. 1998 May;60(1):271-8
– reference: 12532313 - Hum Psychopharmacol. 2003 Jan;18(1):29-38
– reference: 6615688 - Br J Clin Pharmacol. 1983 Aug;16(2):139-44
– reference: 12191761 - J Neurosci Methods. 2002 Jul 30;118(1):89-96
– reference: 15164911 - Sleep. 2004 May 1;27(3):536-40
– reference: 1475567 - Sleep. 1992 Dec;15(6):526-36
– reference: 15541420 - Eur J Pharmacol. 2004 Nov 19;504(3):185-9
– reference: 12088844 - Brain Res. 2002 Jul 5;943(1):105-11
– reference: 2703975 - J Pharmacol Exp Ther. 1989 Mar;248(3):1283-8
– reference: 15060505 - Clin Pharmacol Ther. 2004 Apr;75(4):259-73
– reference: 15816789 - J Clin Psychiatry. 2005 Apr;66(4):469-76
– reference: 11192136 - Clin Ther. 2000 Dec;22(12 ):1443-61
– reference: 10823400 - Psychopharmacology (Berl). 2000 Apr;149(3):203-16
– reference: 7782486 - J Clin Psychopharmacol. 1995 Apr;15(2):132-7
– reference: 10572343 - Eur Psychiatry. 1999 Jun;14(3):167-71
– reference: 26096 - Psychol Med. 1978 May;8(2):325-9
– reference: 2198296 - J Clin Psychopharmacol. 1990 Jun;10(3):184-9
– reference: 7263792 - J Chromatogr. 1981 Jun 5;210(2):311-8
– reference: 16168393 - Brain Res. 2005 Oct 12;1059(1):72-82
– reference: 16223479 - Eur J Pharmacol. 2005 Oct 17;522(1-3):63-71
– reference: 9417012 - JAMA. 1997 Dec 24-31;278(24):2170-7
– reference: 9766695 - Psychiatry Clin Neurosci. 1998 Aug;52(4):439-43
– reference: 11198056 - J Psychopharmacol. 2000;14(4):378-86
– reference: 9400006 - J Pharmacol Exp Ther. 1997 Dec;283(3):1305-22
– reference: 6763207 - Pharmacotherapy. 1982 Sep-Oct;2(5):255-65
– reference: 186223 - Clin Pharmacol Ther. 1976 Dec;20(6):682-9
– reference: 2871178 - J Pharmacol Exp Ther. 1986 May;237(2):649-58
– reference: 9989364 - Sleep. 1999 Feb 1;22(1):33-42
– reference: 6124991 - Psychopharmacology (Berl). 1982;76(3):201-8
– reference: 7816739 - Pharmacol Res. 1994 Aug-Sep;30(2):105-15
– reference: 9749703 - Eur J Neurosci. 1998 Feb;10(2):409-14
– reference: 1881993 - Psychopharmacology (Berl). 1991;104(1):1-5
– reference: 12559374 - Eur J Pharmacol. 2003 Jan 24;460(2-3):139-44
– reference: 8739204 - Eur J Pharmacol. 1996 Apr 11;300(3):163-71
SSID ssj0000484
ssj0068394
Score 2.0596616
Snippet Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of appropriate...
Rationale Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of...
Rationale: Insomnia is a common and disabling complaint for which there is a need for improved treatments. Successful drug discovery relies on the use of...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 943
SubjectTerms Adult
Animals
Biological and medical sciences
Caffeine
Central Nervous System Stimulants
Clinical trials
Comparative analysis
Cross-Over Studies
Disease Models, Animal
Disorders of higher nervous function. Focal brain diseases. Central vestibular syndrome and deafness. Brain stem syndromes
Dose-Response Relationship, Drug
Double-Blind Method
Electroencephalography
Electromyography
GABA Agonists - pharmacology
GABA Agonists - therapeutic use
Human subjects
Humans
Hypnotics and Sedatives - pharmacology
Hypnotics and Sedatives - therapeutic use
Insomnia
Male
Medical sciences
Nervous system (semeiology, syndromes)
Neurology
Neuropharmacology
Pharmacology
Pharmacology. Drug treatments
Polysomnography
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Pyridines - pharmacology
Rats
Rats, Sprague-Dawley
Reference Values
Reproducibility of Results
Rodents
Serotonin Uptake Inhibitors - pharmacology
Serotonin Uptake Inhibitors - therapeutic use
Sleep - drug effects
Sleep Initiation and Maintenance Disorders - chemically induced
Sleep Initiation and Maintenance Disorders - physiopathology
Sleep Initiation and Maintenance Disorders - prevention & control
Telemetry
Trazodone - pharmacology
Title A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers
URI https://www.ncbi.nlm.nih.gov/pubmed/17225163
https://www.proquest.com/docview/218956203
https://www.proquest.com/docview/19640830
https://www.proquest.com/docview/70266783
Volume 191
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBddC2MwRtt9Ze0yPYw-jJjJlizZTyMZDWXQEEYLeTP6sKDQOdnsPuS_352lxPShfbKN9QE66fST7u53hHxVqRWKp2mipNOJcAb0oNQmAWhqC6jEtcB45-uFvLoVv1b5KvrmtNGtcqcTe0Xt1hbvyL_DVgRQPmP8x-Zvgkmj0LgaM2i8IEfIXIYeXWqlBkUsMAYzfEgAAoGRmWM8WV7sLJysJxTNMMcBnq2lyhL2aI96vdEtDJcPeS6eBqL9hjQ_Jm8ikqTTIPoTclA3p-TldbSVn5KLZWCl3k7ozRBk1U7oBV0OfNXbt2Q1pR3uWPfxXnBCrfa-hkYSOLCD6B3t8-XQtafoe91RjBj709xpeKEwg1qqG0dDROWWor4DaQGsfEdu55c3P6-SmHAhsSLnXeIdl9zI1BfaOqEkq7UuYYR85kvlCq-1yZ0pGDelMc6pzPrcMw3r2Bdpah1_Tw6bdVN_JBTNo1mqlcgzLyScg31Z1kznJpV1CUp2RNhuiCsb2cgxKcZ9tedR7qVS9X53IJWKjci3fZVNoOJ4rvD4kdyGGkjgx5QckbOdIKu4bNtqP8lG5Mv-L6w3NKLopl4_tBUSmAFsZU-XUHCsBQgAbXwI82PoW4H2BAD86dm-z8ircIGMXpXn5LD791B_BuTTmXE_v8fkaDqfzRbwnF0ulr__A7WtAbM
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwED6NTgIkhGD8KoPND7AH1AgnduzkAaEBmzq2VhXqpL4FO46lSSMtJBPqH8X_yDlOGu1he9tbotiOlLvcfefzfQfwToY5lywMAymMCrjRaAeF0gFC0zzBSUxxV-88mYrxOf--iBdb8K-rhXHHKjub2Bhqs8zdHvlHdEUI5SPKPq9-B65plEuudh00vFacFuu_GLFVn06-oXjfR9Hx0fzrOGibCgQ5j1kdWMME0yK0icoNl4IWSqXoKG1kU2kSq5SOjU4o06nWxsgot7GlCnXVJmGYG4br3oNtzjCSGcD2l6Pp7Edv-rmr-vQ3AqGH54BmroItTrqcKm0oTCPXVcFF80JGAb3mFR-tVIUCsr6zxs3Qt3GBx0_gcYtdyaFXtqewVZQ7cH_SZud34GDmebDXIzLvy7qqETkgs54he_0MFoekdj7yst2JHJFcWVvgIsFFaVDZDGk69JClJe60d01cjdqv8kLhBUGdrYgqDfE1nGviLCzqBwLZ53B-J9J4AYNyWRavgLiEbBQqyePIcoGRt03TgqpYh6JI0awPgXafOMtb_nPXhuMy2zA3N1LJmpN-KJWMDuHDZsrKk3_cNnjvmtz6GY4ykEoxhN1OkFlrKKpso9ZD2N88xT_cpW1UWSyvqsxRpiFQpjePkBhII-jANV56_ejfLdFeI-R-feu79-HBeD45y85Opqe78NBvX7sznW9gUP-5Kt4i7qr1XqvtBH7e9Q_2H40rPy4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1RT9RAEJ4gJsSEGEXFE4V9UB7MNWy77W77YAwRLyBC7gGSe6u73W5Cgr3Dlpj7af47Z7rtNTzAG29t2t0mndmZb3dmvgH4qMIiViIMAyWtDmJr0A5KbQKEpkWKg4SOqd757FweX8Y_ZslsDf71tTCUVtnbxNZQ23lBZ-QH6IoQykdcHLguK2J6NPm6uAmogRQFWvtuGl5DTsvlX9y91V9OjlDUn6Jo8v3i23HQNRgIijgRTeCskMLI0KW6sLGSvNQ6Q6fpIpcpmzqtTWJNyoXJjLFWRYVLHNeoty4Nw8IKnPcJPFUiCWmJqZkanEBM9Z_-RiII8WzQgmrZkrSPrvKWzDSi_gq0r5cqCvgd_7i50DWKyvkeG_eD4NYZTl7A8w7FskOvdi9hray2YOOsi9Nvwf7UM2Ivx-xiKPCqx2yfTQeu7OUrmB2yhrzldXcmOWaFdq7ESYKryqLaWdb26mFzxyjvu2FUrfa7utJ4wVB7a6Yry3w155KRrUVNQUj7Gi4fRRZvYL2aV-VbYBSajUKt4iRyscQ9uMuykuvEhLLM0MCPgPe_OC86JnRqyHGdrzicW6nkbc4fSiXnI_i8GrLwNCAPvbx7R27DCCIP5EqOYKcXZN6ZjDpfKfgI9lZPca1TAEdX5fy2zok8DSEzv_8NhVtqhB84x7bXj-HbCi03gu93D357DzZwWeU_T85Pd-CZP8em5M73sN78uS0_IABrzG6r6gx-Pfba-g_0EkH-
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+translational%2C+caffeine-induced+model+of+onset+insomnia+in+rats+and+healthy+volunteers&rft.jtitle=Psychopharmacology&rft.au=Paterson%2C+Louise+M&rft.au=Wilson%2C+Sue+J&rft.au=Nutt%2C+David+J&rft.au=Hutson%2C+Peter+H&rft.date=2007-05-01&rft.pub=Springer+Nature+B.V&rft.issn=0033-3158&rft.eissn=1432-2072&rft.volume=191&rft.issue=4&rft.spage=943&rft_id=info:doi/10.1007%2Fs00213-006-0672-0&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=1231721161
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon